NASDAQ: MOBIMobia Medical Inc Stock
$9.06+0.25 (+2.84%)
Updated Sep 25, 2026
MOBI Price
$9.06
Fair Value Price
N/A
Market Cap
$301.62M
52 Week Low
$8.45
52 Week High
$15.25
P/E
N/A
P/B
1.75x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
0.13
Operating Cash Flow
N/A
Beta
-0.29
Next Earnings
Nov 10, 2026
Ex-Dividend
N/A
Next Dividend
N/A
MOBI Overview
Mobia Medical, Inc. develops and commercializes neurostimulation medical devices, including implantable systems for stroke rehabilitation and other neurological conditions. The company provides neurostimulation systems and devices that combine vagus nerve stimulation with therapy to address chronic neurological conditions. Its main product, the Vivistim System, is an FDA-approved implantable device designed to aid in the rehabilitation of upper limb motor function in post-stroke patients. The paired VNS platform is used to help patients relearn movements and improve motor deficits, and it is being developed for additional chronic neurologic conditions such as tinnitus. The company supports healthcare professionals, patients, and caregivers with information and resources related to its offerings. The company serves healthcare professionals and organizations involved in stroke rehabilitation and chronic neurological conditions, as well as patients and caregivers within the healthcare sector. The company was founded in 2007 and is based in Austin, Texas.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine MOBI's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Be the first to know about important MOBI news, forecast changes, insider trades & much more!
MOBI News
Overview
Due Diligence Score
–
Industry Average (30)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how MOBI scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
MOBI is good value based on its book value relative to its share price (1.75x), compared to the US Medical Devices industry average (3.03x)
P/B vs Industry Valuation
MOBI's short-term assets ($192.15M) exceed its short-term liabilities ($14.47M)
Short-term Liabilities Financials
MOBI's short-term assets ($192.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
There are 30 more MOBI due diligence checks available for Premium users.
Valuation
MOBI price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
1.75x
Industry
3.03x
MOBI is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
MOBI's financial health
Profit margin
Revenue
$13.5M
Net Income
-$21.0M
Profit Margin
-155.8%
Assets to liabilities
Assets
$195.3M
Liabilities
$22.7M
Debt to equity
0.13
MOBI's short-term assets ($192.15M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
MOBI's short-term assets ($192.15M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
MOBI's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
-$15.7M
Investing
-$1.5M
Financing
$138.6M
MOBI vs Medical Device Stocks
Mobia Medical Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.